On April 23, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 peptides are returning to Category 1 under FDA compounding regulations — restoring their availability through licensed compounding pharmacies under physician prescription. This is a significant policy development. It is also widely misunderstood.

This article covers: what the reclassification actually does, which peptides are affected, what it does not change for research compound sourcing, and what researchers and clinicians need to know.

Life Link Research products are for research purposes only. Nothing in this article constitutes medical advice.

What Happened on April 23, 2026

HHS Secretary Kennedy, working with the FDA under the administration’s broader health policy agenda, announced the restoration of approximately 14 peptides to Category 1 under the FDA’s compounding list framework. “Category 1” substances are those bulk drug substances that can be used in compounding without requiring FDA approval of each individual compounded preparation — provided the compounding is done by a licensed pharmacy for specific patient prescriptions.

The Category 1 restoration reverses the FDA’s 2021–2023 removal of these peptides from the compounding list, which had restricted their availability through the prescription channel.

Peptides included in the reclassification (based on April 2026 announcement):
– BPC-157 (Body Protection Compound)
– Thymosin Alpha-1 (TA-1)
– TB-500 (Thymosin Beta-4 fragment)
– Epithalon / Epitalon
– Selank
– Semax
– Ipamorelin
– CJC-1295
– KPV
– LL-37
– Dihexa
– GHK-Cu
– DSIP (Delta Sleep-Inducing Peptide)
– PT-141 (Bremelanotide)

Verify current status with FDA guidance — this list may be updated.

What Category 1 Restoration Actually Means

What it does:
– These peptides can now be legally compounded by licensed 503A and 503B compounding pharmacies
– Patients can obtain prescriptions for these compounds from physicians or nurse practitioners
– This restores the legal pathway that existed before the 2021–2023 removal from the compounding list
– It is a significant positive development for patients and prescribers who want access to these compounds via the medical system

What it does NOT do:
– It does not make these compounds available over-the-counter or without a prescription
– It does not change the regulatory status of research-grade peptide vendors selling under a “for research purposes only” framework
– It does not apply to general consumer access
– It does not constitute FDA approval of these peptides as drugs
– It does not remove any enforcement risk for vendors who are not licensed compounding pharmacies

The reclassification operates entirely within the prescription compounding framework. Compounding pharmacies and research chemical vendors operate under completely separate legal frameworks. One change in the compounding framework does not alter the other.

How This Affects Life Link Research and Research Compounds

Short answer: the reclassification does not change Life Link Research’s product offering or legal framework.

Life Link Research sells research-grade peptides under a “for research purposes only” positioning. This is a distinct framework from compounding pharmacy sales under prescription. The two regulatory channels are:

Channel	Legal basis	Who uses it	Prescription required
Compounding pharmacy	FD&C Act §503A/503B, compounding list	Licensed pharmacies, prescribing physicians, patients	Yes — physician Rx required
Research chemical vendor	Research-use-only framework	Researchers, laboratories	No — research-only; not for human use

The April 23, 2026 reclassification expands access through the compounding pharmacy channel. It does not change the research chemical vendor channel.

For researchers: Life Link Research continues to source and document the same compounds — BPC-157, Thymosin Alpha-1, and others from the reclassification list — as research chemicals with six-panel third-party COAs, available without prescription for laboratory research.

For individuals seeking compounds for clinical or personal use: the reclassification is relevant because these compounds are now more accessible through a prescribing physician and licensed compounding pharmacy. That is the appropriate channel for clinical use.

Research vs. Clinical: Two Different Contexts

Use case	Appropriate channel
Laboratory research, in vitro studies, animal research	Research chemical vendor (Life Link Research)
Personal clinical use under physician supervision	Compounding pharmacy under prescription

These are complementary channels, not competitors. The reclassification benefits the clinical channel. It does not affect the research channel.

Why the Reclassification Happened

The removal of these peptides from the compounding list in 2021–2023 was controversial. Researchers and clinicians argued the FDA’s reasoning was inconsistent: peptides with significant clinical interest and safety records were categorized alongside controlled substances and high-risk compounds. The reclassification under HHS Secretary Kennedy represents a policy reversal — acknowledging that these compounds deserve cleaner access pathways.

The policy context is the broader health policy agenda under the Kennedy-led HHS, which has taken a more favorable stance toward alternative and peptide-based approaches in clinical medicine. This is a fluid regulatory environment. The SAFE Drugs Act (H.R. 6509) — which would move in the opposite direction for GLP-1 compounds — remains in committee. Researchers should monitor both developments.

Frequently Asked Questions

Does the RFK Jr. peptide reclassification mean BPC-157 is now legal?

BPC-157 was already available as a research chemical for laboratory use. The reclassification restores it to Category 1 in the compounding list, meaning licensed compounding pharmacies can now prepare it under physician prescription. It does not change its availability as a research chemical. It does not make it available for general consumer purchase without a prescription.

Can I now buy BPC-157 without a prescription because of the reclassification?

No — not through the clinical/compounding channel. If you are buying as a researcher for laboratory use, the research chemical framework has not changed. If you are seeking BPC-157 for personal clinical use, you should consult a physician who can prescribe it through a compounding pharmacy.

Does this change what Life Link Research sells?

No. Life Link Research already stocks BPC-157, Thymosin Alpha-1, and other reclassified peptides as research chemicals with full third-party COA documentation. The reclassification’s expansion of the compounding pharmacy channel does not change our research-only product positioning or sourcing standards.

What is the difference between a compounding pharmacy peptide and a research-grade peptide?

Compounding pharmacy peptides are prepared by licensed pharmacies for specific patients under physician prescription. Research-grade peptides are sourced from chemical suppliers for laboratory research. Both require quality documentation, but the regulatory frameworks, oversight structures, and intended uses are different.

Are GLP-1 compounds (semaglutide, tirzepatide) included in the reclassification?

No. The April 2026 reclassification did not include GLP-1 compounds such as semaglutide or tirzepatide. These compounds have active FDA-approved drug equivalents (Ozempic/Wegovy, Mounjaro/Zepbound), which places them under different compounding restrictions. The proposed SAFE Drugs Act would further restrict their research compound sales.

BPC-157 Research Compound →
Thymosin Alpha-1 Research Compound →

All Life Link Research products are for research purposes only. Not for human use.